TICKERNERD
Menu
FBLGFBLGHealthcare · Biotechnology

FBLG Stock Forecast: FibroBiologics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$1.06
−7.83% on the day

The 2 Wall Street analysts covering FibroBiologics, Inc. hold a median 12-month price target of $13 — +1079.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.1M
Ticker Nerd rank
36 / 100
Median analyst target
$13
Analysts covering
2
Total return, dividends reinvested
1W
+8.6%
1M
+24.4%
YTD
−76.4%
1Y
−91.0%
From 52W high
−91.5%
From 52W low
+69.1%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FBLG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores FibroBiologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
76
Issuance
62
Revisions
59
Growth
46
Volatility
46
Quality
14
Value
11
Momentum
2

Size (94): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26FBLGHigh $19Median $13Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
1 Buy1 Hold0 Sell
Low $6Median $13High $19

The green dot is the last close — the median target sits +1079.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Aug 2026HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
4 May 2026Maxim GroupDowngradeHold—
4 May 2026Maxim GroupDowngradeHold—
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026D. Boral CapitalDowngradeHold—
12 Mar 2026D. Boral CapitalMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
2 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025HC Wainwright & Co.MaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—
17 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FBLG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

FBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

FibroBiologics, Inc. (FBLG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 60% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−660.1%

Higher than 2% of US stocks

Return on assets
−95.8%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

FBLG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBLGFibroBiologics, Inc.$7.1M
36
ERNAErnexa Therapeutics, Inc.$7.0M
36
NIKINiki Biosolutions, Inc.$7.2M
12
PCSAProcessa Pharmaceuticals, Inc.$6.8M
14
ACXPAcurx Pharmaceuticals, Inc.$7.4M
34
ALZNAlzamend Neuro, Inc.$7.4M
16
AIMAIM ImmunoTech, Inc.$6.7M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own FibroBiologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FBLG news & analysis

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

PRNewsWire · 11 Aug 2026positive

FibroBiologics announced that the USPTO has issued U.S. Patent No. 12,691,147 covering methods and compositions for using fibroblasts to facilitate engraftment of insulin-producing islets in the treatment of Type 1 diabetes, with potential applications extending to other cell and tissue transplantation procedures.

Why it matters — This expands FibroBiologics' IP portfolio for its fibroblast platform beyond diabetes into broader transplantation applications, reinforcing the company's patent position with over 270 patents issued and pending.

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

PRNewsWire · 5 Aug 2026positive

FibroBiologics announced that the European Patent Office has granted its patent covering Sox9-based gene therapy for converting fibroblasts into cartilage-producing cells, supporting the company's orthopedics and degenerative disc programs.

Why it matters — This European patent strengthens FibroBiologics' intellectual property protection for its gene therapy approach to cartilage regeneration in key markets outside the U.S.

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

PRNewsWire · 31 July 2026positive

FibroBiologics reported its second quarter 2026 financial results and provided a corporate update, including that the first patients have been dosed in its Phase 1/2 clinical trial evaluating CYWC628 for diabetic foot ulcers, with interim results expected in the second half of 2026.

Why it matters — The initiation of patient dosing brings the company's lead wound care candidate one step closer to potential interim data, a key milestone for a clinical-stage biotechnology firm.

FAQ

Frequently asked questions about FBLG stock

What is the FBLG stock price forecast for 2026-2027?

The 2 Wall Street analysts covering FibroBiologics, Inc. have a median 12-month price target of $13, with estimates ranging from $6 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBLG stock a buy right now?

Of the 2 analysts covering FibroBiologics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks FibroBiologics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBLG?

As at 15 Aug 2026, FibroBiologics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will FBLG stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1079.2% from the last close, and Ticker Nerd's factor model ranks FibroBiologics, Inc. 36 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBLG stock forecast for 2030?

No analyst covering FibroBiologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $19 over the next 12 months.

How has FBLG stock performed over the past year?

FibroBiologics, Inc. returned -91.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does FibroBiologics, Inc. do?

Fibrobiologics Inc. is a cutting-edge biotechnology company involved in the field of regenerative medicine.

What is the latest news on FBLG?

The most recent item we track (PRNewsWire, 11 Aug 2026): "FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets". FibroBiologics announced that the USPTO has issued U.S. Patent No. 12,691,147 covering methods and compositions for using fibroblasts to facilitate engraftment of insulin-producing islets in the treatment of Type 1 diabetes, with potential applications extending to other cell and tissue transplantation procedures.

Company

About FibroBiologics, Inc.

Fibrobiologics Inc. is a cutting-edge biotechnology company involved in the field of regenerative medicine. This company's primary focus is on the development of fibroblast-based technologies and therapies aimed at repairing and regenerating damaged tissues. Fibrobiologics uses fibroblast cells, which are critical for tissue maintenance and wound healing, to create innovative treatments for a variety of conditions, including chronic wounds, degenerative diseases, and age-related conditions. The firm heavily engages in research and development, working to harness the natural capabilities of fibroblasts in addressing unmet medical needs. The role of Fibrobiologics Inc. in the financial market is significant due to its potential impact on the healthcare sector, as advancements in regenerative medicine could lead to major breakthroughs in patient care and treatment efficacy. Within the broader biotechnology industry, Fibrobiologics plays a crucial role, contributing to the ongoing evolution of next-generation therapies that are likely to enhance the quality of life for many patients.

CEO Mr. Peter O'Heeron · 15 employees · United States · https://fibrobiologics.com